- Home
- ADXN vs IMRN Comparison
ADXN vs IMRN Comparison
Compare ADXN & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- IMRN
- Stock Information
- Founded
- ADXN 2002
- IMRN 1994
- Country
- ADXN Switzerland
- IMRN Australia
- Employees
- ADXN N/A
- IMRN N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- IMRN Health Care
- Exchange
- ADXN Nasdaq
- IMRN Nasdaq
- Market Cap
- ADXN 8.1M
- IMRN 9.2M
- IPO Year
- ADXN N/A
- IMRN N/A
- Fundamental
- Price
- ADXN $9.00
- IMRN $1.88
- Analyst Decision
- ADXN Strong Buy
- IMRN Strong Buy
- Analyst Count
- ADXN 1
- IMRN 1
- Target Price
- ADXN $30.00
- IMRN $5.00
- AVG Volume (30 Days)
- ADXN 7.6K
- IMRN 25.2K
- Earning Date
- ADXN 06-19-2025
- IMRN 07-07-2025
- Dividend Yield
- ADXN N/A
- IMRN N/A
- EPS Growth
- ADXN N/A
- IMRN N/A
- EPS
- ADXN 0.10
- IMRN N/A
- Revenue
- ADXN $278,508.00
- IMRN $4,048,286.00
- Revenue This Year
- ADXN $86.57
- IMRN N/A
- Revenue Next Year
- ADXN N/A
- IMRN N/A
- P/E Ratio
- ADXN $0.74
- IMRN N/A
- Revenue Growth
- ADXN N/A
- IMRN 82.90
- 52 Week Low
- ADXN $6.51
- IMRN $1.50
- 52 Week High
- ADXN $13.27
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- ADXN 55.39
- IMRN 58.70
- Support Level
- ADXN $8.02
- IMRN $1.68
- Resistance Level
- ADXN $9.78
- IMRN $1.94
- Average True Range (ATR)
- ADXN 0.73
- IMRN 0.09
- MACD
- ADXN 0.02
- IMRN 0.02
- Stochastic Oscillator
- ADXN 32.94
- IMRN 76.92
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.